|
시장보고서
상품코드
2050977
종양 용해성 바이러스 요법 시장 : 제품 유형별, 용도별, 개발 단계별, 유통 채널별, 지역별Oncolytic Virus Therapy Market, By Product Type, By Application , By Development Stage, By Distribution Channel, By Region |
||||||
종양 용해성 바이러스 요법 시장은 2026년에 2,240만 달러로 추정되고, 2033년까지 1억 1,090만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 25.7%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 2,240만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 25.70% | 2033년 시장 규모 예측 : | 1억 1,090만 달러 |
종양 용해성 바이러스 요법는 변형된 바이러스를 이용하여 건강한 세포를 손상시키지 않고 암세포를 선택적으로 표적화하여 파괴하는 유망한 암 치료법입니다. 암 치료에 바이러스를 이용하는 개념은 20세기 초로 거슬러 올라갑니다. 당시 연구진은 바이러스 감염 환자에서 종양이 퇴행하는 것을 관찰했습니다. 이 분야는 1990년대 유전공학의 발전과 함께 탄력을 받았고, 과학자들은 바이러스를 변형시켜 종양 특이성과 치료 효과를 높일 수 있게 되었습니다. 종양 용해성 바이러스는 암세포에 감염되어 내부에서 증식함으로써 세포 용해를 유도하거나 종양에 대한 면역 반응을 자극할 수 있습니다. 현재 진행 중인 연구는 바이러스 플랫폼의 최적화, 병용요법 개발, 다양한 유형의 암에 대한 종양 용해성 바이러스 요법의 적용 확대에 초점을 맞추었습니다. 학계, 제약사, 연구기관 간의 협력이 새로운 종양 용해성 바이러스 요법법 개발을 촉진하고 있으며, 암 치료 접근법의 발전에 큰 기대를 모으고 있습니다.
시장 역학
세계 종양 용해성 바이러스 요법제 시장은 바이러스 공학의 발전, 암 생물학에 대한 이해의 심화, 성공적인 임상시험, 그리고 혁신적인 암 치료법에 대한 니즈 증가로 인해 강력한 성장세를 보이고 있습니다. 또한, 새로운 암 적응증 발굴, 치료 성과 향상을 위한 병용요법, 맞춤형 의료 접근, 그리고 특성을 강화한 차세대 바이러스 개발은 가까운 미래에 밝은 시장 기회를 가져올 것으로 기대되고 있습니다. 시장 동향으로는 바이러스 치료 플랫폼, 표적 전달 시스템, 면역 조절 전략의 발전, 이 분야의 제조 및 상업화 과제에 대한 대응 등이 있습니다. 또한, 시장 진출기업들은 제휴를 통한 신약 개발에 집중하고 있으며, 이는 세계 종양 용해성 바이러스 요법제 시장의 성장을 견인할 것으로 예측됩니다. 예를 들어, 2023년 6월 29일, 후기 임상 단계의 바이오 제약 기업인 Genelux Corporation과 후기 임상 단계의 바이오 제약 기업인 TVAX Biomedical, Inc. 방법을 주장하는 특허가 미국 특허청에 의해 부여되었다고 발표했습니다. 이 특허는 Genelux와 TVAX가 V2ACT 면역치료제 개발 및 시험을 위해 설립한 합작회사인 V2ACT Therapeutics, LLC에 독점적으로 라이선스를 부여했습니다. 특허기간 연장이 없을 경우, 특허의 유효기간은 2036년으로, V2ACT 면역요법에 대한 실질적인 지적재산권 보호가 강화될 것으로 보입니다.
그러나 임상적 증거의 부족, 투여 및 유통상의 어려움, 치료에 따른 높은 비용, 그리고 치료의 부작용이 시장 성장을 저해할 것으로 예측됩니다. 온콜로이드 바이러스 치료의 효율을 극대화하고 보다 광범위한 보급을 위해서는 이러한 과제를 극복하는 것이 필수적입니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 저해요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계 종양 용해성 바이러스 요법 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 종양 용해성 바이러스 요법 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 종양 용해성 바이러스 요법제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 종양 용해성 바이러스 요법 시장 : 제품 유형별, 2021년-2033년
제5장 종양 용해성 바이러스 요법 시장 : 용도별, 2021년-2033년
제6장 종양 용해성 바이러스 요법 시장 : 개발 단계별, 2021년-2033년
제7장 종양 용해성 바이러스 요법 시장 : 유통 채널별, 2021년-2033년
제8장 종양 용해성 바이러스 요법 시장 : 지역별, 2021년-2033년
제9장 경쟁 구도
제10장 섹션
LSH 26.06.15Oncolytic Virus Therapy Market is estimated to be valued at USD 22.4 Mn in 2026 and is expected to reach USD 110.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 25.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 22.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 25.70% | 2033 Value Projection: | USD 110.9 Mn |
Oncolytic virus therapy is a promising approach to cancer treatment that utilizes modified viruses to selectively target and destroy cancer cells while sparing healthy cells. The concept for viruses for cancer treatment dates back to the early 20th century, when researchers observed tumor regression in patients with viral infections. The field gained momentum in the 1990s with advancements in genetic engineering, enabling scientists to modify viruses to enhance the tumor-specificity and therapeutic efficacy. Oncolytic viruses can infect cancer cells, replicate within them, and induce cell lysis or stimulate immune responses against the tumor. Ongoing research focuses on optimizing viral platforms, developing combination therapies, and expanding the application of oncolytic virus therapy to various cancer types. Collaborations between academia, pharmaceutical companies, and research institutions drive the development of novel oncolytic virus therapies and hold promise for advancing cancer treatment approaches.
Market Dynamics
The global oncolytic virus therapy market is witnessing strong growth on account of growing advancements in viral engineering, increasing understanding of cancer biology, successful clinical trial results, and the need for innovative cancer treatments. Moreover, exploring new cancer indications, combining therapies for improved outcomes, personalized medicine approaches, and the development of next-generation viruses with enhanced characteristics are expected to bring bright market opportunities in the near future. The market trends include advancements in virotherapy platforms, targeted delivery systems, immune modulation strategies, and addressing manufacturing and commercialization challenges in the field. Moreover, market players are focused on developing novel drugs by collaborating, which is expected to drive the growth of global oncolytic virus therapy market. For instance, on June 29, 2023, Genelux Corporation, a late clinical-stage biopharmaceutical company, and TVAX Biomedical, Inc., a late clinical-stage biopharmaceutical company, announced that the U.S. Patent and Trademark Office granted a patent claiming methods of combining vaccine-enhanced adoptive T cell therapy with oncolytic virus adjunct therapy. The patent has been exclusively licensed to V2ACT Therapeutics, LLC, a joint venture between Genelux and TVAX that was established for the purpose of developing and testing V2ACT immunotherapy. The patent expiry, prior to any patent term extension, will be in 2036 and will add substantial intellectual property protection for V2ACT immunotherapy.
However, limited clinical evidence, delivery and distribution challenges, high costs associated with treatment, and side effects of treatment are expected to hamper market growth. Overcoming these challenges is essential to maximizing the efficiency and broader adoption of oncolytic virus therapies.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global oncolytic virus therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study Amgen Inc., Merck & Co., Inc., Oncolytics Biotech Inc., Circio Holding ASA, Akamis Bio, Vyriad, Inc., SillaJen Biotherapeutics, Cold Genesys Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Replimune Group Inc., Genelux Corporation, Synthetic Biologics, Inc., Lokon Pharma AB, and Elicera Therapeutics.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global oncolytic virus therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncolytic virus therapy market.
Market Segmentation
- By Product Type (Revenue, USD Mn, 2021 - 2033)
- Herpes simplex virus
- Adenovirus
- Vaccinia virus
- Reovirus
- Measles virus
- Others (Newcastle disease virus, Vesicular stomatitis virus)
- By Application (Revenue, USD Mn, 2021 - 2033)
- Melanoma
- Breast cancer
- Head and neck cancer
- Bladder Cancer
- Prostate Cancer
- Lung Cancer
- Others (Colorectal Cancer, and among Others)
- By Development Stage (Revenue, USD Mn, 2021 - 2033)
- Commercial
- Pipeline Phase
- Pre-clinical
- Phase I
- Phase II
- Phase III
- By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in Oncolytic Virus Therapy Market
- Amgen Inc.
- Merck & Co., Inc.
- Oncolytics Biotech Inc.
- Circio Holding ASA
- Akamis Bio
- Vyriad, Inc.
- SillaJen Biotherapeutics
- Cold Genesys Inc.
- Sorrento Therapeutics, Inc.
- Takara Bio Inc.
- Replimune Group Inc.
- Genelux Corporation
- Synthetic Biologics, Inc.
- Lokon Pharma AB
- Elicera Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Oncolytic Virus Therapy Market, By Product Type
- Global Oncolytic Virus Therapy Market, By Application
- Global Oncolytic Virus Therapy Market, By Development Stage
- Global Oncolytic Virus Therapy Market, By Distribution Channel
- Global Oncolytic Virus Therapy Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Advancements in Viral Engineering
- Increasing Understanding of Cancer Biology
- Successful Clinical Trial Results
- Need for Innovative Cancer Treatments
- Restraints
- High cost associated with treatment
- Side effects of treatment
- Opportunities
- Exploring new cancer indications
- Combining therapies for improved outcomes
- Personalized medicine approaches
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Oncolytic Virus Therapy Market , By Product Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Herpes Simplex Virus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Adenovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Vaccinia virus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Reovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Measles virus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Others (Newcastle disease virus, Vesicular stomatitis virus)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
5. Oncolytic Virus Therapy Market , By Application, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Breast cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,( USD Mn)
- Head and neck cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,( USD Mn)
- Bladder Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,( USD Mn)
- Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,( USD Mn)
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Others (Colorectal Cancer, and among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
6. Oncolytic Virus Therapy Market, By Development Stage, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Commercial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Pipeline Phase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Pre-clinical
- Phase I
- Phase II
- Phase III
7. Oncolytic Virus Therapy Market , By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
8. Oncolytic Virus Therapy Market , By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2021 - 2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- U.K
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- China
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033,(USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Oncolytics Biotech Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Circio Holding ASA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Akamis Bio
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Vyriad, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- SillaJen Biotherapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cold Genesys Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sorrento Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takara Bio Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Replimune Group Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Genelux Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Synthetic Biologics, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lokon Pharma AB
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Elicera Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
